Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens

about

Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens

Item

http://www.wikidata.org/entity/Q57138571

description

scientific article published on 26 July 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@en

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@nl

type

Item

label

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@en

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@nl

prefLabel

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@en

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@nl

P1476

Potent therapeutic efficacy of ...... lloma virus E6 and E7 antigens

@en

P2093

Annemarie Boerma

http://www.w3.org/2001/XMLSchema#string

Karl Ljungberg

http://www.w3.org/2001/XMLSchema#string

Maria L Knudsen

http://www.w3.org/2001/XMLSchema#string

Peng Peng Ip

http://www.w3.org/2001/XMLSchema#string

Stephanie van de Wall

http://www.w3.org/2001/XMLSchema#string

P2860

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

The causal relation between human papillomavirus and cervical cancer.

Papillomaviruses and cancer: from basic studies to clinical application

A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects

DNA and RNA-based vaccines: principles, progress and prospects.

MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Human papillomavirus infection: biology, epidemiology, and prevention.

Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations

CD8+ T-cell memory in tumor immunology and immunotherapy.

P304

e1487913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2018.1487913

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Liljestrom

Toos Daemen

Hans W Nijman

P577

2018-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30288352

http://www.w3.org/2001/XMLSchema#string

P921

immunology

P932

6169581

http://www.w3.org/2001/XMLSchema#string